Search Patents
  • METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE
    Publication number: 20230398206
    Abstract: The invention relates to a method of eliciting an immune response in a human subject showing no signs or symptoms of an active SARS-CoV-2 infection comprising administering intra-dermally to the human subject an immunogenic composition comprising the Spike protein (S protein) of SARS-CoV-2 or a fragment thereof.
    Type: Application
    Filed: October 27, 2021
    Publication date: December 14, 2023
    Inventors: David Berd, James Passin
  • PEPTIDE BASED PROBES FOR THE DETECTION OF SARS-COV-2
    Publication number: 20230194525
    Abstract: A highly specific molecular diagnostic for the detection of an intended target protein within a matter of minutes employing a peptide beacon, the peptide beacon having a stem section having two ends attached to a fluorophore and a quencher and a loop section having a receptor sequence for binding with the intended target protein, the two ends forming a coiled-coil structure when the receptor sequence is unbound with the intended target protein and an open-coil structure when the receptor sequence is bound with the intended target protein, wherein the peptide beacons are able to provide a signal for the detection of the receptor binding domain of the intended target protein, such as SARS-CoV-2 spike protein, by the stem section transitioning from the coiled-coil structure to the open-coil structure that moves the fluorophore away from the quencher, resulting in an increase in the fluorescence yield of the peptide beacon.
    Type: Application
    Filed: April 29, 2022
    Publication date: June 22, 2023
    Inventors: Pranam CHATTERJEE, Raghava Manvitha PONNAPATI, Soumya Pratap TRIPATHY, Joseph M. JACOBSON
  • Coronavirus vaccine
    Patent number: 11547673
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: January 10, 2023
    Assignee: BioNTech SE
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • COMPUTING SYSTEM AND METHOD OF DETERMINING TARGET EPITOPE ON SPECIFIC VIRUS FOR FACILITATING DESIGN OF MUTATION-TOLERABLE VACCINE
    Publication number: 20230099381
    Abstract: A method includes: determining a mutation frequency for each residue in a wild-type spike protein of a specific virus; for each residue in the protein, counting a total number of contact residues related to said each residue and P antibodies based on P entries of protein structure data; for each residue in the protein, for a condition that said each residue mutates into one common amino acid residue, determining a normalized binding free energy value using a pre-established model based on the protein structure data, and determining a mutation effect score based on the mutation frequency, the total number of contact residues and the normalized binding free energy value; generating a mutation effect epitope map related to the mutation effect scores determined for all residues in the protein and all common amino acid residues; and determining, based on the map, a region in the protein as a target epitope.
    Type: Application
    Filed: September 23, 2022
    Publication date: March 30, 2023
    Inventors: Yi-Ting CHEN, Sing-Han HUANG, Ching-Yung LIN, Xiang-Yu LIN, Cheng-Tang WANG
  • METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH SARS-COV-2
    Publication number: 20240025972
    Abstract: Provided herein are methods of treating or preventing SARS-CoV-2 infection comprising modulating interactions between the SARS-CoV-2 spike protein and plasma membrane-expressed host cell proteins, as well as methods of identifying modulators of such interactions.
    Type: Application
    Filed: May 22, 2023
    Publication date: January 25, 2024
    Inventor: Nadia MARTINEZ-MARTIN
  • SARS-CoV-2 polypeptide inhibitors directed against the Env TM domain and methods of treatment using said inhibitors
    Patent number: 11548919
    Abstract: Methods for treating coronavirus infection, such as an infection caused by SARS-CoV-2, in a subject in need thereof include administering to the subject a therapeutically effective amount of a composition comprising an isolated polypeptide targeting the spike protein and the transmembrane region of the coronavirus envelope protein. Compositions include isolated polypeptides complementary to residues 30-38 of the envelope protein transmembrane region.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: January 10, 2023
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Alaa F. Nahhas, Thomas Webster
  • CORONAVIRUS VACCINE
    Publication number: 20240075165
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
    Type: Application
    Filed: November 16, 2022
    Publication date: March 7, 2024
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • Coronavirus vaccine
    Patent number: 11925694
    Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: March 12, 2024
    Assignee: BioNTech SE
    Inventors: Ugur Sahin, Alptekin Güler, Andreas Kuhn, Alexander Muik, Annette Vogel, Kerstin Walzer, Sonja Witzel, Stephanie Hein, Özlem Türeci
  • LICHENASE-COVID-19 BASED VACCINE
    Publication number: 20210283243
    Abstract: The present invention includes an immunogenic protein, nucleic acid, plant and immunization comprising a fusion protein that has at least 90% amino acid identity to an amino acid sequence of a modified thermostable lichenase (LicKM) polypeptide as set forth in SEQ ID NO:9, wherein the LicKM polypeptide comprises an N-terminus, a C-terminus, and an inner loop region, and wherein a Receptor Binding Domain (RBD) or a Receptor Binding Motif (RBM) of a coronavirus spike protein is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the LicKM polypeptide.
    Type: Application
    Filed: March 11, 2021
    Publication date: September 16, 2021
    Inventor: Sylvain Marcel
  • USE OF TRANSFERRIN, TRANSFERRIN RECEPTOR AND ANTIBODY THEREOF IN PREPARATION OF ANTI-SARS-CoV-2 DRUG
    Publication number: 20230060040
    Abstract: The present disclosure provides use of transferrin, a transferrin receptor and an antibody thereof in the preparation of an anti-SARS-CoV-2 drug. Use of the transferrin, the transferrin receptor or the transferrin receptor antibody in the preparation of an anti-SARS-CoV-2 drug is provided. Both surface plasmon resonance (SPR) and immunofluorescence confirm that the SARS-CoV-2 binds to the transferrin receptor through SARS-CoV-2 spike protein; the transferrin and/or the transferrin receptor antibody competitively bind(s) to the transferrin receptor of the body, or the transferrin receptor competitively binds to a site of the SARS-CoV-2 to inhibit binding of the SARS-CoV-2 to the transferrin receptor of the body; thus, the opportunity that the SARS-CoV-2 infects cells is blocked, and the antiviral effect of the body is realized.
    Type: Application
    Filed: June 29, 2020
    Publication date: February 23, 2023
    Inventors: Ren LAI, Xiaozhong PENG, Xiaopeng TANG, Zhiyi LIAO, Shuaiyao LU, Hongqi LIU
  • VACCINE COMPOSITION FOR PREVENTING OR TREATING INFECTION OF SARS-COV-2
    Publication number: 20230257425
    Abstract: Provided is a recombinant protein for preventing or treating infection of SARS-Coronavirus-2 antigen comprising an extended receptor binding domain (RBD) of a spike protein of SARS-Coronavirus-2, and a vaccine composition comprising thereof. Also the present invention relates to a method for preventing infection of SARS-Coronavirus-2 by administering the recombinant antigen protein to a subject. The present invention can prevent COVID-19 infection. The present invention can be used as a vaccine.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 17, 2023
    Inventors: Teawoo KWON, YoonJae LEE, Eun-som KIM, Seung-hye HONG, Ki-weon SEO, Sujeen LEE
  • Diagnostics for sars virus
    Publication number: 20070092938
    Abstract: This invention relates to Severe Acute Respiratory Syndrome associated coronavirus (SARS virus) isolated and recombinant proteins, in particular the nucleocapsid (N) protein and spike (S) protein, as well as fragments thereof and their use in the diagnosis, treatment and prevention of Severe Acute Respiratory Syndrome (SARS). The proteins and fragments carry epitopes that are specific for the SARS virus. Thus, detection methods based on these proteins or fragments as well as the monoclonal antibodies against these proteins or fragments are specific for the SARS virus.
    Type: Application
    Filed: February 4, 2004
    Publication date: April 26, 2007
    Applicant: Temasek Life Sciences Laboratory
    Inventors: Jimmy Kwang, Ai Ling, Eng Ooi, Hiok Chng
  • COMPOSITIONS INCORPORATING SULFATED POLYSACCHARIDES FOR INHIBITING SARS-COV-2
    Publication number: 20230201249
    Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via competitive binding to SARS-CoV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-CoV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 ?M, and low cytotoxicity, making it promising for clinical use. While established SARS-CoV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.
    Type: Application
    Filed: April 2, 2021
    Publication date: June 29, 2023
    Inventors: Robert John LINHARDT, So-Young KIM, Weihua JIN, Jonathan Seth DORDICK, Fuming ZHANG, Seok-Joon KWON, Paul S. KWON, Keith FRASER
  • Inactivation of Genome Enveloped within Coronavirus Spherical or Pleomorphic Particles or Shells to Form a Vaccine
    Publication number: 20230226172
    Abstract: Vaccine based on ethanol inactivated pathogens, or part thereof, are described herein. Also disclosed are certain vaccines for treating COVID-19 or other coronavirus related diseases is created by deactivating the genome, genetic material or RNA encapsulated within the shell of virus without eliminating the spikes or spike protein, which both attaches the virus to a host cell and is detected by the body to produce antibodies. Treatment of an active coronavirus with a material such as an effective amount of ethanol will both penetrate the shell and deactivate the genetic material which causes the disease, for preparation of a vaccine.
    Type: Application
    Filed: June 11, 2021
    Publication date: July 20, 2023
    Inventors: Schossau M. Tom, Kurup K. Shree, Schossau Jorden
  • VACCINE COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS
    Publication number: 20210353741
    Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
    Type: Application
    Filed: March 30, 2021
    Publication date: November 18, 2021
    Inventors: David Evander Anderson, Anne-Catherine Fluckiger
  • HIGH PHASE-PURITY GROWTH OF 1T'-TRANSITION METAL DICHALCOGENIDE MONOLAYERS
    Publication number: 20240043694
    Abstract: A method of forming a 1T?-phase transition metal dichalcogenide monolayer. A transition metal precursor and a first solvent are mixed to form a first mixture. A non-oxygen chalcogen or non-oxygen chalcogen precursor and a second solvent are mixed to form a second mixture. The first mixture is rapidly injected into the second mixture at a temperature between approximately 250 and 350° C. to form a third mixture. 1T?-transition metal dichalcogenide monolayers are recovered from the third mixture. The transition metals may be molybdenum or tungsten, while the non-oxygen chalcogens may be sulfur, selenium, or tellurium. The 1T?-transition metal dichalcogenide monolayers can be grown on a variety of metal substrates to form metal@ 1T?-transition metal dichalcogenide monolayer heterostructures. A flexible 4H-Au@1T?-WS2/SiO2/PDMS SERS tape was fabricated to detect the SARS-CoV-2 spike protein. The tape is capable of attomole-level detection of SARS-CoV-2 spike protein, for real-time monitoring of COVID-19.
    Type: Application
    Filed: July 25, 2023
    Publication date: February 8, 2024
    Inventors: Hua ZHANG, Zijian LI, Li ZHAI
  • ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19
    Publication number: 20230381297
    Abstract: The present invention relates to a composition for raising an immune response in an animal which prevents or decreases the risk of a coronavirus infection and decreases severity of disease. In particular, the invention relates to vaccines and/or immunogenic compositions for raising an immune response in an animal which prevents or decreases the risk of the SARS-CoV-2 disease named COVID-19 by the World Health Organization. The composition comprises an attenuated poxvirus, and especially a vaccinia virus, wherein the attenuated poxvirus genome comprises a coronavirus SARS-CoV-2 nucleic acid sequence encoding the spike protein polypeptide and or the membrane protein polypeptide and or nucleocapsid protein polypeptide and or envelope protein polypeptide or an immunogenic or functional part of any of these.
    Type: Application
    Filed: May 15, 2023
    Publication date: November 30, 2023
    Inventors: Natalie PROW, Paul Howley, Tamara Cooper, John D. Hayball, Kerrilyn R. Diener, Liang Liu, Preethi Eldi
  • VACCINE COMPOSITIONS FOR THE TREATMENT OF CORONAVIRUS
    Publication number: 20220233682
    Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include a spike protein from the Beta variant of SARS-Cov-2.
    Type: Application
    Filed: January 12, 2022
    Publication date: July 28, 2022
    Inventors: David Evander Anderson, Anne-Catherine Fluckiger
  • ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19
    Publication number: 20210299245
    Abstract: The present invention relates to a composition for raising an immune response in an animal which prevents or decreases the risk of a coronavirus infection and decreases severity of disease. In particular, the invention relates to vaccines and/or immunogenic compositions for raising an immune response in an animal which prevents or decreases the risk of the SARS-CoV-2 disease named COVID-19 by the World Health Organization. The composition comprises an attenuated poxvirus, and especially a vaccinia virus, wherein the attenuated poxvirus genome comprises a coronavirus SARS-CoV-2 nucleic acid sequence encoding the spike protein polypeptide and or the membrane protein polypeptide and or nucleocapsid protein polypeptide and or envelope protein polypeptide or an immunogenic or functional part of any of these.
    Type: Application
    Filed: March 25, 2021
    Publication date: September 30, 2021
    Inventors: Natalie PROW, Paul Howley, Tamara Cooper, John D. Hayball, Kerrilyn R. Diener, Liang Liu, Preethi Eldi
  • Lateral Flow Device for Detection of Neutralizing Antibodies Against SARS-COV-2
    Publication number: 20230168245
    Abstract: The present disclosure provides a lateral flow device, and methods of use of the device, for accurately and rapidly detecting a COVID-19 infection in a subject. The lateral flow device described herein detects in a liquid sample from the subject the presence or absence of neutralizing and non-neutralizing anti-S1 spike antibodies as IgM and IgG types. The anti-S1 antibodies neutralizing antibodies (e.g., both IgM and IgG) can block binding between ACE2 antigen and S1 spike protein which is the basis for the design of the lateral flow device.
    Type: Application
    Filed: April 23, 2021
    Publication date: June 1, 2023
    Applicant: Sorrento Therapeutics, Inc.
    Inventor: Henry Hongjun Ji
Narrow Results

Filter by US Classification